July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Tolerability of novel myopia control spectacle designs
Author Affiliations & Notes
  • Joe Rappon
    SightGlass Vision, Inc., Southlake, Texas, United States
  • Jill Woods
    Centre for Ocular Research & Education, University of Waterloo, Waterloo, Ontario, Canada
  • Debbie Jones
    Centre for Ocular Research & Education, University of Waterloo, Waterloo, Ontario, Canada
  • Lyndon William Jones
    Centre for Ocular Research & Education, University of Waterloo, Waterloo, Ontario, Canada
  • Footnotes
    Commercial Relationships   Joe Rappon, SightGlass Vision, Inc, (E); Jill Woods, SightGlass Vision, Inc. (F); Debbie Jones, SightGlass Vision, Inc. (F); Lyndon Jones, SightGlass Vision, Inc. (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5845. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joe Rappon, Jill Woods, Debbie Jones, Lyndon William Jones; Tolerability of novel myopia control spectacle designs. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5845. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Myopia is a global epidemic that is increasing in both prevalence and severity, and high myopia (>5-6 D) leads to vision-threatening retinal complications later in life. Treatments to prevent myopia progression are urgently needed, particularly treatments amenable for young children (<10 years). We conducted a prospective, randomized, subject-masked, 3-arm clinical study to assess the pediatric acceptability across three iterations of a novel spectacle lens design.

Methods : Participants were healthy, myopic (-1.00 to -4.00 DS) children, aged 6-12 years. Twenty-one habitual spectacle wearers were randomized to one of three lens designs for 2 weeks. Each lens design had a clear central aperture and peripheral patterns designed to modulate peripheral contrast to three different levels. The primary outcome variables were distance visual acuity, contrast sensitivity, and subjective responses of acceptability assessed using a questionnaire. Other outcome variables included a parent questionnaire, near visual acuity, and axial length measurements.

Results : All 21 eligible subjects completed the study. High-contrast distance visual acuity in both high and low room illumination were at high levels, not different to refraction acuity levels (p>0.05). There were no differences between any of the lens designs for high-contrast, high-illumination distance and near acuity; high-contrast, low-illumination distance acuity or contrast sensitivity. Results from the subject questionnaire indicated that the experience with lens designs 1 and 2 were similar to each other and to their habitual spectacles. By some measures related to vision clarity and cosmesis, subjects preferred their habitual spectacles to lens design 3. Results from the parent questionnaire supported that wearing lens design 3 posed more difficulties for the children in some areas compared to the other designs. All three lens designs showed a trend toward reduction in axial length over the 2 weeks of lens wear, with lens design 1 reaching statistical significance in both eyes (p<0.05).

Conclusions : All three lens designs provided similarly high levels of distance and near visual acuity and contrast sensitivity and were tolerable for the study duration. Based on patient-reported subjective data, lens designs 1 and 2 performed better than lens design 3. The axial length reductions noted is consistent with a therapeutic effect of slowing myopia progression, and merits further investigation.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×